OSCC

Caris Life Sciences to Showcase Research at 2024 SGO Annual Meeting on Women's Cancer

Retrieved on: 
Wednesday, March 13, 2024
Diagnosis, PR, UCS, NCI, Ovarian cancer, Promise, OSCC, Survival, EEC, Exome sequencing, Glomus tumor, TMB, Patient, Neoplasm, NGS, Biomarker, Research, DNA, RNA, Cancer, AI, SGO, Carcinosarcoma, MD, Endometrial cancer, Medicine, Abstract, POA, Prognosis, Poster, ETS, Medical imaging

IRVING, Texas, March 13, 2024 /PRNewswire/ -- Caris Life Sciences®(Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular science and AI, announced today that the company and collaborators within the Caris Precision Oncology Alliance™ (POA) will collectively present three studies across multiple gynecological tumor types at the 2024 SGO Annual Meeting on Women's Cancer, March 16-18, 2024, in San Diego. The findings demonstrate the power of Caris' comprehensive multi-modal database, generated by examining every gene, to enable novel insights into cancer that could have profound effects on a patient's diagnosis, prognosis, care plan and response to treatment.

Key Points: 
  • The findings demonstrate the power of Caris' comprehensive multi-modal database, generated by examining every gene
    "We are proud to return and present an array of precision oncology research at this year's SGO Annual Meeting.
  • The Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) criteria classify four molecular subtypes of endometrial tumors (ET).
  • Poster and abstract summaries highlighting the Caris research presented at SGO 2024 will be available onsite at Caris' booth (#601).
  • The POA includes 91 cancer centers, academic institutions, research consortia and healthcare systems, including 43 NCI-designated cancer centers, collaborating to advance precision oncology and biomarker-driven research.

HUD Unveils New Report to Overcome Barriers to Offsite Construction

Retrieved on: 
Wednesday, February 1, 2023
OSCC, NIBS, HUD, Ace Powell, University, National Institute of Building Sciences, United States Department of Housing and Urban Development, JD, CPS, Housing, Research, U.S. Department of Defense Strategy for Operating in Cyberspace, Partnership, Education, MOD, Industrial design, Oil, Renewable energy, Civil engineering, Off-site

WASHINGTON, Feb. 1, 2023 /PRNewswire/ -- The U.S. Department of Housing and Urban Development, in partnership with the National Institute of Building Sciences and MOD X, has released the Offsite Construction for Housing: Research Roadmap, a strategic report that presents the key knowledge gaps and research needs to overcome the barriers and challenges to offsite construction.

Key Points: 
  • Offsite construction has the potential to deliver more affordable and accessible single and multifamily housing at scale.
  • This stands in considerable contrast to more mature international offsite construction industries, such as those in the UK, Japan, and Sweden.
  • "We applaud HUD for undertaking this research effort to overcome barriers and level the playing field for all construction methods to help alleviate the housing crisis."
  • NIBS staff and members of the OSCC have supported federal and private off-site construction research projects, including toolkits, roadmaps, and reports for the off-site industry.

Cortexyme Announces Preclinical Data Highlighting Potential Therapeutic Benefits of Atuzaginstat for the Treatment of High-Risk Oral Potentially Malignant Disorders

Retrieved on: 
Wednesday, March 9, 2022
Research, Seniors, Dental, Clinical Trials, Biotechnology, Health, Consumer, Pharmaceutical, Science, Nasdaq, Safety, Laboratory, Twitter, Incidence, Geng, University, B cell, IND, Otorhinolaryngology, Reyes, U.S. Securities and Exchange Commission, Dave, Survival, FDA, Squamous cell carcinoma, Inflammation, Wen, Cancer, Association, OSCC, Katz, Escape Room, Human, IHC, OPMD, MD, PVL, News, PMD, Disease, CIS, Gao, Investigational New Drug, Degenerative disease, Brain, HIV disease progression rates, Food and Drug Administration, Doctor of Philosophy, Patient, Tumor-associated macrophage, Security (finance), PD-1, Esophageal cancer, SEC, Recurrence, PD-L1, Division, Forward-looking statement, Tams, Vaccine, Pharmaceutical industry, Porphyromonas gingivalis

We look forward to strategically advancing the development of atuzaginstat for the potential treatment of high-risk OPMDs through both internal and external development opportunities.

Key Points: 
  • We look forward to strategically advancing the development of atuzaginstat for the potential treatment of high-risk OPMDs through both internal and external development opportunities.
  • Cortexyme is finalizing a Phase 2 trial design for its lysine gingipain inhibitor, atuzaginstat (COR388), as a potential new indication to prevent the development of O/HNSCC.
  • Cortexyme in vitro studies have demonstrated that PD-L1 induced by P. gingivalis can be blocked by atuzaginstat.
  • I am excited and encouraged by the growing evidence that supports the potential of atuzaginstat for the treatment of P. gingivalis-positive, high-risk OPMDs.